IDXX
IDEXX Laboratories, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth +6.2% ·
share flow +11.3% ·
net new positions +5.9%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 7 | 0 | 471.56K | $245.77M | n/a | n/a |
| Q2 2026 | 168 | 0 | 55.55M | $29.26B | +7 | −6 |
| Q1 2026 | 170 | +1 | 53.67M | $30.16B | +5 | −5 |
| Q4 2025 | 168 | +2 | 58.18M | $39.32B | +3 | n/a |
| Q3 2025 | 21 | +1 | 29.88M | $19.09B | +1 | −1 |
| Q2 2025 | 18 | 0 | 26.38M | $14.14B | +1 | −1 |
| Q1 2025 | 15 | -2 | 9.43M | $3.96B | n/a | −2 |
| Q4 2024 | 17 | -1 | 9.47M | $3.92B | n/a | −1 |
| Q3 2024 | 17 | +1 | 5.70M | $2.88B | +1 | n/a |
| Q2 2024 | 16 | n/a | 5.12M | $2.49B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 2.26M | +1.8% | $1.14B | 0.1% | ▲ Add | 2 | SEC ↗ ×2 |
| 2 | T. Rowe Price ✦ | 1.54M | +20.9% | $776.45M | 0.1% | ▲ Add | 2 | SEC ↗ ×2 |
| 3 | Norges Bank ✦ (passive) | 999.28K | +0.5% | $504.86M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 4 | Millennium Management ✦ | 155.77K | +20.0% | $78.70M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 5 | Arrowstreet Capital ✦ | 133.57K | +5.2% | $67.48M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 6 | D. E. Shaw & Co. ✦ | 126.22K | +387.2% | $63.77M | 0.1% | ▲ Add | 2 | SEC ↗ ×2 |
| 7 | Two Sigma Investments ✦ | 111.70K | +115.7% | $56.43M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 8 | Point72 Asset Management ✦ | 96.46K | New | $48.73M | 0.2% | New | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 74.81K | +35.6% | $37.80M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 10 | AQR Capital Management ✦ | 52.53K | +77.8% | $26.54M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 11 | Renaissance Technologies ✦ | 35.70K | +73.3% | $18.04M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Adage Capital Partners ✦ | 33.95K | -35.8% | $17.15M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | Marshall Wace ✦ | 28.27K | +37.9% | $14.28M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 23.10K | -70.1% | $11.67M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 15 | Gotham Asset Management ✦ | 19.36K | +23.6% | $9.78M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 16 | Bridgewater Associates ✦ | 12.75K | -60.7% | $6.44M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | Fisher Asset Management ✦ | 678 | -18.4% | $342,882 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $48.73M | 0.2% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,302 holders, 70.72M shares, $38.50B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 2.20K sh · $1.17M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology